Replies to post #3531 on RespireRx Pharmaceuticals Inc (fka RSPI)

[fearfrost]

lol, very nice

[DewDiligence]

>Pfizer has watched torcetrapib, asenapine, and indiplon turn from potentially replacing all of that loss, or more, to write-offs on its balance sheet.<

Let’s not forget Macugen for AMD. PFE paid EyeTech (now part of OSIP) more money in milestones than the drug sold during its entire time on the market.

[dominate]

That was a fast response from Pfizer..lol


Pfizer Buying BioRexis Pharmaceutical
Thursday February 1, 10:37 am ET
Pfizer Paying Undisclosed Amount for BioRexis Pharmaceutical and Its Diabetes Pipeline


NEW YORK (AP) -- Drug developer Pfizer Inc. said Thursday it is buying privately held BioRexis Pharmaceutical Corp. for an undisclosed amount.
BioRexis is developing several treatments for diabetes. The technology being used to develop those treatments uses protein engineering and could have the potential to improve drug tolerability and reduce dosing frequency, Pfizer said.

Shares of Pfizer rose 35 cents to $26.59 on the New York Stock Exchange in morning trading